The PPARγ agonist FMOC-l-leucine protects both mature and immature brain

Biomedicine and Pharmacotherapy

Volumn 62, Issue 4, 2008, Pages 259-263

  Maurois, Pierre ^a   Rocchi, Stéphane ^b   Pages, Nicole ^c   Bac, Pierre ^a   Stables, James P ^d   Gressens, Pierre ^e,f   Vamecq, Joseph ^b  

^a CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE STRASBOURG   (France)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^e HÔPITAL ROBERT DEBRÉ   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Anticonvulsant; FMOC l leucine; Immature brain; Injury; Neuroprotection; PPAR

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; IBOTENIC ACID; MAGNESIUM; N (9 FLUORENYLMETHOXYCARBONYL)LEUCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; SODIUM CHANNEL BLOCKING AGENT; (N (9 FLUORENYLMETHOXYCARBONYL) ) L LEUCINE; (N-(9-FLUORENYLMETHOXYCARBONYL)-)-L-LEUCINE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 2-CHLORO-5-NITROBENZANILIDE; ANILIDE; ANTICONVULSIVE AGENT; DRUG DERIVATIVE; LEUCINE; NEUROPROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICONVULSANT ACTIVITY; ARTICLE; AUDIOGENIC SEIZURE; BRAIN INJURY; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; GRAY MATTER; MOUSE; NEUROPROTECTION; NEWBORN; NONHUMAN; PRIORITY JOURNAL; WHITE MATTER; ANIMAL; BRAIN; DRUG POTENTIATION;

ANILIDES; ANIMALS; ANTICONVULSANTS; BRAIN; IBOTENIC ACID; LEUCINE; MICE; NEUROPROTECTIVE AGENTS; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 43049168553     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2007.10.014     Document Type: Article

References (20)

1. Ikonomidou C., Bittigau P., Koch C., Genz K., Hoerster F., Felderhoff-Mueser U., et al. Neurotransmitters and apoptosis in the developing brain. Biochem Pharmacol 62 (2001) 401-405
2. Olney J.W. New insights and new issues in developmental neurotoxicology. Neurotoxicology 23 (2002) 1-10
3. Vamecq J., Maurois P., Bac P., Bailly F., Bernier J.L., Stables J.P., et al. Potent mammalian cerebroprotection and neuronal cell death inhibition are afforded by a synthetic antioxidant analogue of marine invertebrate cell protectant ovothiols. Eur J Neurosci 18 (2003) 1110-1120
4. Barbier O., Pineda Torra I., Duguay Y., Blanquart C., Fruchart J.C., Glineur C., et al. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscl Throm Vas 22 (2002) 717-726
5. Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., and Hirsch E.C. Protective action of the peroxisome proliferator-activated receptor-γ agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 82 (2002) 615-624
6. Kamenov B., Katic V., and Cekic S. Role of peroxisome proliferator-activated receptor-g in pathogenesis of diseases mediated by inflammation, in malignancy, and in lipid and glucose metabolism disorders. Arch Oncol 12 Suppl. 1 (2004) 30-32
7. Torra L.P., Chinetti G., Duval C., Fruchart J.C., and Staels B. Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Curr Opin Lipidol 12 (2001) 245-254
8. Gressens P., Marret S., Hill J.M., Brenneman D.E., Gozes I., Fridkin I., et al. Vasoactive intestinal peptide prevents excitotoxic hypoxic-like cell death in the murine developing brain. J Clin Invest 100 (1997) 390-397
9. Husson I., Mesplès B., Bac P., Vamecq J., Evrard P., and Gressens P. Melatoninergic neuroprotection of the murine periventricular white matter against neonatal excitotoxic challenge. Ann Neurol 51 (2002) 82-92
10. Marret S., Mukendi R., Gadisseux J.F., Gressens P., and Evrard P. Effect of ibotenate on brain development: an excitotoxic mouse model of microgyria and posthypoxic like lesions. J Neuropath Exp Neur 54 (1995) 358-370
11. Durlach J., Bac P., Bara M., and Guiet-Bara A. Physiopathology of symptomatic and latent forms of central nervous hyperexcitability due to magnesium deficiency: a current general scheme. Magnes Res 13 (2000) 293-302
12. Bac P., Maurois P., Dupont C., Pages N., Stables J.P., Gressens P., et al. Magnesium deficiency-dependent audiogenic seizures (MDDASs) in adult mice: a nutritional model for discriminatory screening of anticonvulsant drugs and original assessment of neuroprotection properties. J Neurosci 18 (1998) 4363-4373
13. Maurois P., Bailly F., Pages N., Bac P., Fourniat J., Dupont C., et al. Chapter 71-The multiple facets of the MDDAS (magnesium deficiency-dependent audiogenic seizure) test: application to the detection of neurotoxic molecules or neuroprotective (antiinflammatory and/or antioxidant) molecules on central nervous hyperexcitability induced by severe magnesium deficiency. In: Rayssiguier Y., Masure A., and Durlach J. (Eds). Advances in magnesium research: nutrition and health (2001), John Libbey, London 419-422
14. Rocchi S., Picard F., Vamecq J., Gelman L., Potier N., Zeyer D., et al. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cells 8 (2001) 737-747
15. A receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice. Epilepsia 45 (2004) 864-867
16. Collin M., Murch O., and Thiemermann C. Peroxisome proliferator-activated receptor-gamma antagonists GW9662 and T0070907 reduce the predictive effects of liposaccharide preconditioning against organ failure caused by endotoxemia. Crit Care Med 34 (2006) 1277-1279
17. Culman J., Zhao Y., Gohlke P., and Herdegen T. PPAR-gamma: therapeutic target for ischemic stroke. Trends Pharmacol Sci 28 (2007) 244-249
18. Picard F., Gehin M., Annicotte J., Rocchi S., Champy M.F., O'Malley B.W., et al. SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell 111 (2002) 931-941
19. Morosetti R., Servidei T., Mirabella M., Rutella S., Mangiola A., Maira G., et al. The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines. Int J Oncol 25 (2004) 493-502
20. Perez-Ortiz J.M., Tranque P., Vaquero C.F., Domingo B., Molina F., Calvos S., et al. Glitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferator-activated receptor-gamma. J Biol Chem 279 (2004) 8976-8985